Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-β-lactamase inhibitor combination, against Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 6, 1999, Pages 1503-1504

  Bantar, Carlos ^a,f   Nicola, Federico ^a   Arenoso, Hector J ^b   Galas, Marcelo ^c   Soria, Liliana ^d   Dana, Diego ^e   Rossi, Alicia ^c   Bianchini, Hebe ^a   Jasovich, Abel ^d  

^a Centro De Educacion Medica e Investigaciones Clinicas Norberto QuirnoEscuela de Medicina   (Argentina)

^b Dto Médico Laboratorios Bagó S A   (Argentina)

^c Instituto Nacional de Microbiologia Dr Carlos GMalbran   (Argentina)

^d Antartida Private Hospital   (Argentina)

^e GADOR S A   (Argentina)

^f Laboratorio de Bacteriologia   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS SULBACTAM; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; TRIFAMOX; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG URINE LEVEL; ENTEROBACTER INFECTION; ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0033002105     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.6.1503     Document Type: Article

References (11)

1. Arlet, G., and A. Philippon. 1991. Construction by polymerase chain reaction and intragenic DNA probes for three main types of transferable beta-lactamases (TEM, SHV and CARB) FEMS Microbiol. Lett. 82:19-26.
2. Bantar, C., M. Micucci, L. Fernandez Canigia, J. Smayevsky, and H. Bianchini. 1993. Synergy characterization for Enterococcus faecalis strains displaying moderately high-level gentamicin and streptomycin resistance. J. Clin. Microbiol. 31:1921-1923.
3. Campoli-Richards, D. M., and R. N. Brogden. 1987. Sulbactam/ampicillin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 33:577-609.
4. Dall, L. L., H. A. Andreeta, J. L. Soutric, and H. J. Arenoso. 1990. Determinación en sangre de amoxicilina y sulbactama luego de una dosis oral única. Cálculo de parámetros farmacocinéticos. Prensa Med. Argent. 77:11-14.
5. Foulds, G. 1986. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev. Infect. Dis. 8(Suppl. 5):S503-S511.
6. Jacobs, M. R., S. C. Aronoff, S. Johenning, D. M. Shlaes, and S. Yamabe. 1986. Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined β-lactamase-producing aerobic gram-negative bacilli. Antimicrob. Agents Chemother. 29:980-985.
7. Labia, R., and M. Barthélémy. 1979. L'enzymogramme des beta-lactamases: adaptation en gel de la methode iodometrique. Ann. Inst. Pasteur Microbiol. 1308:295-304.
8. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. National Committee for Clinical Laboratory Standards. 1997. Methodology for the serum bactericidal test. Proposed guideline M21-P. National Committee for Clinical Laboratory Standards. Wayne, Pa.
10. Retsema, J. A., A. R. English, A. Girard, et al. 1986. Sulbactam/ampicillin: in vitro spectrum potency, and activity in models of acute infections. Rev. Infect. Dis. 8(Suppl. 5):S528-S534.
11. Slocombe, B., A. S. Beale, R. J. Boom, K. E. Griffin, R. J. Masters, R. Sutherland, et al. 1984. Antibacterial activity in vitro and in vivo of amoxycillin in the presence of clavulanic acid, p. 29-49. In McGraw-Hill (ed.), Progress and perspectives on beta-lactamase inhibition: a review of Augmentin. Post-graduate medicine. Custom communications, New York, N.Y.